225Ac-PD-29875 / PeptiDream - LARVOL DELTA

Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models. (SNMMI 2025) - "To assess biodistribution, 64Cu-PD-29875, 177Lu-PD-29875 or 225Ac-PD-29875 was dosed to BxPC3-CLDN18.2 xenograft mice, and the percentage of injected dose per gram of tissue in tumors and major organs was quantified by cut and count method. PD-29875 is a promising radiotheranostic peptide for CLDN18.2-expressing solid tumors including pancreatic cancer."

Clinical • Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer (Businesswire) - "PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company...announced its second wholly-owned peptide radiopharmaceutical development candidate arising from the company’s ongoing internal peptide radiopharmaceutical discovery and development efforts. The development candidate ('PD-29875') is a novel first-in-class highly-selective macrocyclic peptide-radioisotope (RI) conjugate against Claudin 18.2 ('CLDN18.2'), a member of the claudin family of proteins that are integral components of tight junctions found in epithelial tissues....PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (²²⁵Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer."

New molecule • Gastric Cancer